Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
News

Aglukkaq asks for US help to control oxycodone

Adam Miller
CMAJ May 14, 2013 185 (8) E317-E318; DOI: https://doi.org/10.1503/cmaj.109-4457
Adam Miller
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Months after the federal health minister ignored expert advice and approved a generic version of the much-abused prescription drug oxycodone, she has now asked for assistance from the United States in controlling the drug’s use.

Federal Health Minister Leona Aglukkaq sent a letter on Mar. 12 to Gil Kerlikowske of the Office of National Drug Control Policy and Dr. Margaret Hamburg, commissioner of the US Food and Drug Administration (FDA), asking for their assistance in working together on the oxycodone (OxyContin) issue.

In the letter, Aglukkaq specifically makes reference to the dangers of the generic version of the drug she approved for manufacture in November 2012, writing that she remains “particularly concerned with the potential for abuse and diversion of pharmaceutical drugs, including generic versions of OxyContin.”

“As neighbours, we have a shared responsibility to require appropriate controls in our respective jurisdictions, for the health and safety of our communities and also to reduce risks of cross-border trafficking,” she states in the letter.

“Preventing the abuse and diversion of pharmaceutical drugs is an area where cooperation between our two countries would be valuable in helping to achieve our common objectives. To this end, I propose that our officials work together to develop joint evidence-based guidance on abuse deterrence that could be used on both sides of the border.”

Aglukkaq made the controversial decision to approve the manufacture of generic forms of oxycodone, despite urgings from every provincial and territorial health minister to, at the very least, delay the decision until more research had been conducted.

Federal NDP Health Critic Libby Davies writes in an email that by deciding to approve generic oxycodone, “the Health Minister has abandoned another complex health issue and left the provinces to deal with the consequences.”

Figure

Deaths in Canada from oxycodone increased by 416% between 1999 and 2004.

Image courtesy of © 2013 Thinkstock

“We heard the warnings from provincial ministers of health and dozens of physicians have warned that its release could gravely increase abuse of the drug, and pose a significant public health risk,” Davies writes in an email.

Meanwhile, across the border, the FDA is waiting for more information on safety and effectiveness before approving new generic forms of oxycodone.

“FDA does not intend to approve the marketing of generic versions of the original formulation of OxyContin until the agency determines whether the original formulation was withdrawn for reasons of safety or effectiveness,” states FDA spokesperson Lisa Kubaska in an email.

Aglukkaq’s decision to approve the generic oxycodone created waves across the border.

On Nov. 21, 2012, Montana’s Attorney General at the time, Steve Bullock wrote to the minister, asking her to “respectfully reconsider” approving the manufacture of generic oxycodone. “I have concerns that allowing easier-to-abuse oxycodone in Canada could undo some of the work that both Canadian and U.S. government and community leaders have accomplished in combating this epidemic,” the letter stated.

That same month, the US Office of National Drug Control Policy sent out an alert regarding the increased risk of the cross-border trafficking of generic oxycodone after six generic pharmaceutical companies were licensed to manufacture the drug. “The potential exists for diversion into the United States because the old formulations, which are easier to abuse, are unavailable in the United States,” the alert stated.

Canada currently ranks as the second largest consumer of prescription opioids in the world behind the US, while deaths from oxycodone increased by 416% between 1999 and 2004.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 185 (8)
CMAJ
Vol. 185, Issue 8
14 May 2013
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Aglukkaq asks for US help to control oxycodone
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Aglukkaq asks for US help to control oxycodone
Adam Miller
CMAJ May 2013, 185 (8) E317-E318; DOI: 10.1503/cmaj.109-4457

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Aglukkaq asks for US help to control oxycodone
Adam Miller
CMAJ May 2013, 185 (8) E317-E318; DOI: 10.1503/cmaj.109-4457
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Saying goodbye to CMAJ News
  • National survey highlights worsening primary care access
  • How Canadian hospitals are decreasing carbon emissions
Show more News

Similar Articles

Collections

  • Topics
    • Canadian government
    • Public health

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire